Tomimaru Y, Ito T, Marubashi S, Kawamoto K, Tomokuni A, Asaoka T, Wada H, Eguchi H, Mori M, Doki Y, Nagano H
Department of Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan.
Department of Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan; Department of Complementary and Alternative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan; The Japan Registry of Pancreas Transplantation, The Japan Society for Pancreas and Islet Transplantation, Osaka, Japan.
Transplant Proc. 2015 Apr;47(3):742-5. doi: 10.1016/j.transproceed.2014.11.052.
Long-term immunosuppression is associated with an increased risk of cancer. Especially, the immunosuppression in pancreas transplantation is more intensive than that in other organ transplantation because of its strong immunogenicity. Therefore, it suggests that the risk of post-transplant de novo malignancy might increase in pancreas transplantation. However, there have been few studies of de novo malignancy after pancreas transplantation. The aim of this study was to analyze the incidence of de novo malignancy after pancreas transplantation in Japan.
Post-transplant patients with de novo malignancy were surveyed and characterized in Japan.
Among 107 cases receiving pancreas transplantation in Japan between 2001 and 2010, de novo malignancy developed in 9 cases (8.4%): post-transplant lymphoproliferative disorders in 6 cases, colon cancer in 1 case, renal cancer in 1 case, and brain tumor in 1 case.
We clarified the incidence of de novo malignancy after pancreas transplantation in Japan.
长期免疫抑制与癌症风险增加相关。特别是，由于胰腺移植的免疫原性较强，其免疫抑制程度比其他器官移植更为强烈。因此，这表明胰腺移植后新发恶性肿瘤的风险可能会增加。然而，关于胰腺移植后新发恶性肿瘤的研究较少。本研究的目的是分析日本胰腺移植后新发恶性肿瘤的发生率。
对日本移植后发生新发恶性肿瘤的患者进行调查并描述其特征。
在2001年至2010年间日本接受胰腺移植的107例患者中，9例（8.4%）发生了新发恶性肿瘤：6例为移植后淋巴细胞增生性疾病，1例为结肠癌，1例为肾癌，1例为脑肿瘤。
我们明确了日本胰腺移植后新发恶性肿瘤的发生率。
